Suzette A. Priola

Dr. Suzette A. Priola


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2000 in Science
Verified
Journal Article
Closed access
PDF file
SPSuzette A. Priola
Suzette A. Priola
ARAnne Raines
Anne Raines
WCWinslow S. Caughey
Winslow S. Caughey
The transmissible spongiform encephalopathies (TSEs) are fatal, neurodegenerative diseases for which no effective treatments are available. The likelihood that a bovine form of TSE has crossed species barriers and infected humans underscores the urgent need to identify anti-TSE drugs. Certain cyclic tetrapyrroles (porphyrins and phthalocyanines) have recently been shown to inhibit the in vitro formation of PrP-res, a protease-resistant protein critical for TSE pathogenesis. We now report that treatment of TSE-infected animals with three such compounds increased survival time from 50 to 300%. The significant inhibition of TSE disease by structurally dissimilar tetrapyrroles identifies these compounds as anti-TSE drugs.

1 February 2003 in Journal of Virology
Verified
Journal Article
Open access
PDF file
IVIna Vorberg
Ina Vorberg
MGMartin H. Groschup
Martin H. Groschup
EPEberhard Pfaff
Eberhard Pfaff
SPSuzette A. Priola
Suzette A. Priola
Transmissible spongiform encephalopathies (TSEs) are neurological diseases that are associated with the conversion of the normal host-encoded prion protein (PrP-sen) to an abnormal protease-resistant form, PrP-res. Transmission of the TSE agent from one species to another is usually inefficient and accompanied by a prolonged incubation time. Species barriers to infection by the TSE agent are of particular importance given the apparent transmission of bovine spongiform encephalopathy to humans. Among the few animal species that appear to be resistant to infection by the TSE agent are rabbits. They survive challenge with the human kuru and Creutzfeldt-Jakob agents as well as with scrapie agent isolated from sheep or mice. Species barriers to the TSE agent are strongly influenced by the PrP amino acid sequence of both the donor and recipient animals. Here we show that rabbit PrP-sen does not form PrP-res in murine tissue culture cells persistently infected with the mouse-adapted scrapie agent. Unlike other TSE species barriers that have been studied, critical amino acid residues that inhibit PrP-res formation are located throughout the rabbit PrP sequence. Our results suggest that the resistance of rabbits to infection by the TSE agent is due to multiple rabbit PrP-specific amino acid residues that result in a PrP structure that is unable to refold to the abnormal isoform associated with disease.

1 February 2009 in Current Opinion in Structural Biology
Verified
Journal Article
Closed access
RMRoger A. Moore
Roger A. Moore
LTLara M Taubner
Lara M Taubner
SPSuzette A. Priola
Suzette A. Priola

3 December 2001 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SPSuzette A. Priola
Suzette A. Priola
Victoria LawsonVictoria Lawson
Victoria Lawson
A key event in the transmissible spongiform encephalopathies (TSEs) is the formation of aggregated and protease‐resistant prion protein, PrP‐res, from a normally soluble, protease‐sensitive and glycosylated precursor, PrP‐sen. While amino acid sequence similarity between PrP‐sen and PrP‐res influences both PrP‐res formation and cross‐species transmission of infectivity, the influence of co‐ or post‐translational modifications to PrP‐sen is unknown. Here we report that, if PrP‐sen and PrP‐res are derived from different species, PrP‐sen glycosylation can significantly affect PrP‐res formation. Glycosylation affected PrP‐res formation by influencing the amount of PrP‐sen bound to PrP‐res, while the amino acid sequence of PrP‐sen influenced the amount of PrP‐res generated in the post‐binding conversion step. Our results show that in addition to amino acid sequence, co‐ or post‐translational modifications to PrP‐sen influence PrP‐res formation in vitro . In vivo , these modifications might contribute to the resistance to infection associated with transmission of TSE infectivity across species barriers.

1 March 2006 in Protein Science
Verified
Journal Article
Open access
PDF file
RMRoger A. Moore
Roger A. Moore
CHChristian Herzog
Christian Herzog
JEJohn Errett
John Errett
DKDavid A. Kocisko
David A. Kocisko
KAKevin M. Arnold
Kevin M. Arnold
SPSuzette A. Priola
Suzette A. Priola
A central feature of transmissible spongiform encephalopathies (TSE or prion diseases) involves the conversion of a normal, protease‐sensitive glycoprotein termed prion protein (PrP‐sen) into a pro‐tease‐resistant form, termed PrP‐res. The N terminus of PrP‐sen has five copies of a repeating eight amino acid sequence (octapeptide repeat). The presence of one to nine extra copies of this motif is associated with a heritable form of Creutzfeld‐Jakob disease (CJD) in humans. An increasing number of octapeptide repeats correlates with earlier CJD onset, suggesting that the rate at which PrP‐sen misfolds into PrP‐res may be influenced by these mutations. In order to determine if octapeptide repeat insertions influence the rate at which PrP‐res is formed, we used a hamster PrP amyloid‐forming peptide (residues 23–144) into which two to 10 extra octapeptide repeats were inserted. The spontaneous formation of protease‐resistant PrP amyloid from these peptides was more rapid in response to an increased number of octapeptide repeats. Furthermore, experiments using full‐length glycosylated hamster PrP‐sen demonstrated that PrP‐res formation also occurred more rapidly from PrP‐sen molecules expressing 10 extra copies of the octapeptide repeat. The rate increase for PrP‐res formation did not appear to be due to any influence of the octapeptide repeat region on PrP structure, but rather to more rapid binding between PrP molecules. Our data from both models support the hypothesis that extra octapeptide repeats in PrP increase the rate at which protease resistant PrP is formed which in turn may affect the rate of disease onset in familial forms of CJD.

1 May 1998 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SPSuzette A. Priola
Suzette A. Priola
BCBruce Chesebro
Bruce Chesebro
Inherited forms of the human transmissible spongiform encephalopathy Creutzfeldt-Jakob disease (CJD) have been associated with mutations in the normal soluble, protease-sensitive form of the host prion protein (PrP-sen). Normal PrP protein contains five copies of a repeating eight-amino acid region, and PrP molecules with six or more copies of this region are associated with disease in familial CJD. It has been hypothesized that these mutations might facilitate spontaneous formation of the abnormal, aggregated protease-resistant PrP isoform, PrP-res, associated with clinical CJD and other transmissible spongiform encephalopathies (TSE). In the present experiments, hamster PrP molecules with 5 (wild-type), 7, 9, or 11 copies of this repeat region were generated and expressed in mouse fibroblast cells or mouse neuroblastoma cells. In mouse fibroblast cells, mutant hamster PrP molecules expressing 7, 9, and 11 copies of the octapeptide repeat sequence showed altered cell surface expression, but both mutant and wild-type hamster PrP-sen molecules demonstrated abnormal properties of aggregation and increased protease resistance. By contrast in mouse neuroblastoma cells, hamster PrP-sen with 5, 9, and 11 octapeptide repeats were expressed normally on the cell surface, but only PrP-sen molecules with 9 or 11 copies of the repeat motif had abnormal properties of aggregation and increased protease resistance. Overall, regardless of cell type, hamster PrP molecules with greater than 7 octapeptide repeats were more aggregated and more protease-resistant than molecules with 7 repeats or less. However, these abnormal molecules were at least 1000-fold less protease-resistant than bona fide PrP-res derived from TSE-infected brain tissue, and they showed no increased ability to form PrP-res in a cell-free system.